Talk:Olanzapine
This page is not a forum for general discussion about Olanzapine. Any such comments may be removed or refactored. Please limit discussion to improvement of this article. You may wish to ask factual questions about Olanzapine at the Reference desk. |
Pharmacology B‑class High‑importance | ||||||||||
|
Medicine: Psychiatry B‑class High‑importance | |||||||||||||
|
/Archive 1 |
This page has archives. Sections older than 31 days may be automatically archived by Lowercase sigmabot III when more than 4 sections are present. |
NYT
Here's an important article that just came out in the NY Times http://www.nytimes.com/2006/12/18/business/18drug.html?hp&ex=1166504400&en=abbfa89f1f363c93&ei=5094&partner=homepage — Preceding unsigned comment added by 71.206.230.233 (talk)
"Illegal promotion" paragraph removed
I've removed the paragraph below. I have no opinion on the drug or its use, or knowledge of the "qui tam" (class action) suits alleged, but it lacks clarity, citations, context, and doesn't make much sense. Please restore the paragraph if you have better sources and wording. 201.171.122.70 (talk) 09:13, 25 January 2013 (UTC)
- ===(removed paragraph) Illegal promotion in US===
- The criminal information alleged that Zyprexa was promoted (1999-2003) in nursing homes and assisted-living facilities for the treatment of disorders such as dementia, Alzheimer’s dementia, depression, anxiety, and sleep problems, and behavioral symptoms such as agitation, aggression, and hostility. The qui tam lawsuits alleged that Zyprexa was promoted (1999-2005) for use in patients of all ages and for the treatment of anxiety, irritability, depression, nausea, Alzheimer’s and other mood disorders. Off-label promotion of pharmaceutical drugs is considered, by the U.S. Food and Drug Administration (FDA), to be a serious crime that undermines their role in drug regulation and public safety.[1]
- I am sorry I think this is very important, please put it back.Booklaunch (talk) 19:56, 12 May 2013 (UTC)
Related news
I would like to suggest something is said about newspapers headlines. Why? bacause I think the medical profession is biased and there should be a counterweight in order to guarantee neutral point of view at wikipedia. — Preceding unsigned comment added by Booklaunch (talk • contribs) 19:58, 12 May 2013 (UTC)
Lead
I am sorry i reverted you summary addition because I feel is completely off topic especially for the first paragraph, should be in later sectionsSevendigits (talk) 15:36, 13 May 2013 (UTC)
- In 2002, British and Japanese regulatory agencies warned that Zyprexa may be linked to diabetes. The FDA issued a similar warning in 2003, but Lilly did not publicly disclose their own findings. Eli Lilly agreed in 2007 to pay up to $500 million to settle thousands of lawsuits from people who claimed they developed diabetes or other diseases after taking Zyprexa. In January 2009 Eli Lilly pled guilty to a criminal misdemeanor charge of illegally marketing Zyprexa for off-label use, and agreed to pay $1.4 billion.[2] Although Lilly had evidence that it is not effective for dementia, Zyprexa was marketed for elderly Alzheimer's patients.[3] The drug carries an F.D.A. warning that it increases the risk of death in older patients with dementia-related psychosis.[4]
- I was expanding the lead to provide a better summary of article, per WP:Lead. A one paragraph lead is too short, and the notable regulatory aspects of this drug, discussed in the body of the article, needs to be mentioned in the intro. Johnfos (talk) 06:52, 15 May 2013 (UTC)
- ^ Cite error: The named reference
Off-label
was invoked but never defined (see the help page). - ^ MSN.com Lilly settles Zyprexa suit for $1.42 billion. The Associated Press, January 15, 2009
- ^ Cronin Fisk, Martha, Lopatto, Elizabeth and Feeley, Jef (June 1, 2009). "Lilly Sold Drug for Dementia Knowing It Didn't Help, Files Show". Bloomberg L.P. Retrieved 2009-09-03.
{{cite news}}
: CS1 maint: multiple names: authors list (link) - ^ Berenson, Alex (December 18, 2006). "Drug Files Show Maker Promoted Unapproved Use". The New York Times. Retrieved 2009-09-03.